News
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...
Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...
“We want to democratize the PCSK9 pathway, because that is the most potent way to lower LDL cholesterol,” Merck Research Laboratories President Dean Li said at an investor conference in late May.
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...
A new study projects that aligning U.S. cholesterol treatment with clinical guidelines could significantly reduce cardiovascular events nationwide. The study, led by researchers at Baltimore-based ...
While Merck faces the inevitable Keytruda patent cliff in 2028, ... MK-0616, an investigational oral drug for lowering LDL cholesterol, is designed to be the first oral PCSK9 inhibitor.
RAHWAY, N.J., June 09, 2025--Merck Announces Positive Topline Results from Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults with Hyperlipidemia ...
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...
Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist. Geopolitical tensions, Fed uncertainty, and fast-moving headlines are driving July volatility.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results